Final results of the PETACC-1 trial of bolus 5-FU/LV vs raltitrexed: An unsuccessful story? by Popov, I, Wils, J, Carrato, A, Sobrero, A, Vincent, M, Kerr, D, Labianca, R, Pignatti, F, Praet, M, Nordlinger, B

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). by Popov, I, Carrato, A, Sobrero, A, Vincent, M, Kerr, D, Labianca, R, Raffaele Bianco, A, El-Serafi, M, Bedenne, L, Paillot, B, Mini, E, Sanches, E, Welch, J, Collette, L, Praet, M, Wils, J

Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients by Hewitt E, Bouche G, Alencar AC, Bigelsen SJ, Radu R, Stoyanova-Beninska V, Carrato A, Valsecchi F, Soler Cantón A, van der Meer HG, García Bermejo ML, Budillon A, Cardone L, Rooman I, Platteeuw H, Baijet J, Fuchs C

Get full text